|
Dr. Von Hoff is currently Professor of Medicine, Molecular and Cellular Biology and Pathology, and Director of the Arizona Cancer Center at The University of Arizona in Tucson. Dr. Von Hoff and his colleagues have been involved in the development of numerous cancer agents, including mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, and CPT-11. He is founder and the Editor Emeritus of Investigational New Drugs The Journal of New Anticancer Agents; an Associate Editor of Clinical Cancer Research; Co-Editor of Oncology Spectrums and is on the editorial board of Anti-cancer Drugs and the International Journal of Oncology. Dr. Von Hoff has published more than 470 papers, 120 book chapters, and more than 800 abstracts. Dr. Von Hoff is the immediate past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology and a member of the FDA’s Oncology Drug Advisory Committee (ODAC). He is a founder of ILEX Oncology Inc. and is co-chair of its Scientific Advisory Board. He is also Co-Director of Clinical Research for US Oncology, Inc. | 